Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27966842 | 0.89 | PDE3A (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL30514296 | 0.85 | LMNA (0.53) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL30514303 | 0.84 | LMNA (0.50) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL3432521 | 0.84 | LMNA (0.52) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL22631542 | 0.84 | LMNA (0.52) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL23496606 | 0.84 | LMNA (0.52) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL5491556 | 0.84 | LMNA (0.52) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL366599 | 0.84 | LMNA (0.52) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL158512 | 0.82 | LMNA (0.51) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL7201752 | 0.82 | LMNA (0.51) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | claimed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | claimed |
| CN-114246906-A | Application of traditional Chinese medicine composition in preparation of medicines for preventing and treating bone marrow suppression | 山东新时代药业有限公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-3609534-A1 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | ModernaTX, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018170245-A1 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | MODERNATX, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| EP-3102215-A2 | 4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION | Riboscience LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015120237-A2 | 4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION | RIBOSCIENCE LLC (US) | 2015-08-13 | — | — | WO | disclosed |
| US-8252768-B2 | Designer therapy of pancreatic tumors | UNIVERSITY OF MIAMI (US) | 2012-08-28 | — | — | US | disclosed |
| US-20090325897-A1 | DESIGNER THERAPY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2009-12-31 | — | — | US | disclosed |
| EP-1520015-A2 | PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE | Knecht, Wolfgang (SE) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004003185-A2 | PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE | KNECHT WOLFGANG (SE) | 2004-01-08 | — | — | WO | disclosed |
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | disclosed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | disclosed |
| EP-0233493-A2 | Process for producing ribonucleosides | Yamasa Shoyu Kabushiki Kaisha (JP) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177695-A1 | Nucleic acid probes and methods | NUDT1, NT5C3B, NT5C2 | LMNA 1665/4885MTOR 4775/4885THRB 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.